Telix Pharmaceuticals Ltd
TLX7.800USD
-0.010-0.13%
收盤 12/19, 16:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Telix Pharmaceuticals Ltd 公司
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd簡介
公司代碼TLX
公司名稱Telix Pharmaceuticals Ltd
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址55 Flemington Road
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編3051
電話61390933855
網址https://telixpharma.com/
公司代碼TLX
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
其他
99.81%
持股股東
持股股東
佔比
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
其他
99.81%
股東類型
持股股東
佔比
Investment Advisor
0.11%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
其他
99.76%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
42.09K
0.01%
+42.09K
--
Jun 30, 2025
Jane Street Capital, L.L.C.
35.10K
0.01%
+35.10K
--
Jun 30, 2025
Private Advisor Group LLC
25.17K
0.01%
+15.03K
+148.20%
Jun 30, 2025
IHT Wealth Management, LLC
13.24K
0%
+13.24K
--
Jun 30, 2025
Vanguard Personalized Indexing Management, LLC
18.48K
0.01%
+18.48K
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Telix Pharmaceuticals Ltd的前五大股東是誰？
Telix Pharmaceuticals Ltd的前五大股東如下：
Fidelity Management & Research Company LLC持有股份：42.09K佔總股份比例：0.01%。
Jane Street Capital, L.L.C.持有股份：35.10K佔總股份比例：0.01%。
Private Advisor Group LLC持有股份：25.17K佔總股份比例：0.01%。
IHT Wealth Management, LLC持有股份：13.24K佔總股份比例：0.00%。
Vanguard Personalized Indexing Management, LLC持有股份：18.48K佔總股份比例：0.01%。
Fidelity Management & Research Company LLC持有股份：42.09K佔總股份比例：0.01%。
Jane Street Capital, L.L.C.持有股份：35.10K佔總股份比例：0.01%。
Private Advisor Group LLC持有股份：25.17K佔總股份比例：0.01%。
IHT Wealth Management, LLC持有股份：13.24K佔總股份比例：0.00%。
Vanguard Personalized Indexing Management, LLC持有股份：18.48K佔總股份比例：0.01%。
Telix Pharmaceuticals Ltd的前三大股東類型是什麼？
Telix Pharmaceuticals Ltd 的前三大股東類型分別是：
Millennium Management LLC
Portland Investment Counsel Inc.
Fidelity Management & Research Company LLC
Millennium Management LLC
Portland Investment Counsel Inc.
Fidelity Management & Research Company LLC
有多少機構持有Telix Pharmaceuticals Ltd(TLX)的股份？
截至2025Q3，共有25家機構持有Telix Pharmaceuticals Ltd的股份，合計持有的股份價值約為456.14K，占公司總股份的0.13% 。與2025Q2相比，機構持股有所增加，增幅為0.06%。
哪個業務部門對Telix Pharmaceuticals Ltd的收入貢獻最大？
在--，--業務部門對Telix Pharmaceuticals Ltd的收入貢獻最大，創收--，占總收入的--% 。
